10-Q
Quarterly Report
10x Genomics, Inc.
TXG
NASDAQ
CIK: 1770787
File #: 001-39035
Balance Sheet
39 line items · 2 periods
XBRL
| Item | Jun 30, 2024 | Dec 31, 2023 |
|---|---|---|
Assets | ||
Current assets: | ||
Cash and cash equivalents | 379,824,000 | 359,284,000 |
Marketable securities | 269,000 | 29,411,000 |
Accounts receivable, net | 91,178,000 | 114,832,000 |
Inventory | 88,272,000 | 73,706,000 |
Prepaid expenses and other current assets | 19,612,000 | 18,789,000 |
Total current assets | 579,155,000 | 596,022,000 |
Property and equipment, net | 263,285,000 | 279,571,000 |
Operating lease right-of-use assets | 60,872,000 | 65,361,000 |
Goodwill | 4,511,000 | 4,511,000 |
Intangible assets, net | 16,658,000 | 16,616,000 |
Other noncurrent assets | 5,187,000 | 3,062,000 |
Total assets | 929,668,000 | 965,143,000 |
Liabilities and stockholders’ equity | ||
Current liabilities: | ||
Accounts payable | 21,248,000 | 15,738,000 |
Accrued compensation and related benefits | 20,078,000 | 30,105,000 |
Accrued expenses and other current liabilities | 42,437,000 | 56,648,000 |
Deferred revenue | 16,436,000 | 13,150,000 |
Products and Services, Excluding Grant Revenue | 16,400,000 | — |
Operating lease liabilities | 10,820,000 | 11,521,000 |
Total current liabilities | 111,019,000 | 127,162,000 |
Operating lease liabilities, noncurrent | 78,662,000 | 83,849,000 |
Deferred revenue, noncurrent | 11,358,000 | 8,814,000 |
Other noncurrent liabilities | 4,571,000 | 4,275,000 |
Total liabilities | 205,610,000 | 224,100,000 |
Stockholders’ equity: | ||
Preferred stock | 0 | 0 |
Common stock | 2,000 | 2,000 |
Additional paid-in capital | 2,106,752,000 | 2,025,890,000 |
Accumulated deficit | (1,382,266,000) | (1,284,420,000) |
Accumulated other comprehensive loss | (430,000) | (429,000) |
Total stockholders’ equity | 724,058,000 | 741,043,000 |
Common Stock | 2,000 | 2,000 |
Additional Paid-in Capital | 2,106,752,000 | 2,025,890,000 |
Accumulated Deficit | (1,382,266,000) | (1,284,420,000) |
Accumulated Other Comprehensive Income (Loss) | (430,000) | (429,000) |
Total liabilities and stockholders’ equity | 929,668,000 | 965,143,000 |